Quantcast

Latest Mapatumumab Stories

2009-01-12 06:23:00

- Albuferon(R) for hepatitis C, LymphoStat-B(R) for lupus and ABthrax(R) for inhalation anthrax all progressing rapidly toward commercialization - - GSK Phase 3 trial of darapladib underway in chronic coronary heart disease - - HGS provides 2009 financial guidance; expects less than $25 million net cash burn - ROCKVILLE, Md., Jan. 12 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) will announce its priority goals for 2009 and report on the Company's progress toward...

2009-01-08 08:38:00

MONTREAL, Jan. 8 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2 study of AEG35156, their targeted antisense therapeutic in mid-stage development for multiple oncology indications. The study, entitled "A Phase 2, Multicenter, Open-Label, Randomized Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given In Combination With Carboplatin/Paclitaxel or the Combination of Carboplatin/Paclitaxel Alone In Patients...

2008-12-09 09:00:00

SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma. Carfilzomib is the first in a new class of specific proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. Sundar Jagannath, M.D., Chief of the...

2008-11-13 03:00:16

ImClone Systems, a developer of novel antibodies to treat cancer, has initiated patient enrollment for its disease-directed Phase II clinical trial of IMC-1121B in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. This open-label Phase II single-arm study is enrolling patients with stage IIIB or IV non-small cell lung cancer. Approximately 40 patients are expected to be enrolled. This study is designed to evaluate the progression-free...

2008-10-30 18:00:29

Cytokinetics, Incorporated (NASDAQ: CYTK), reported revenues from research and development collaborations of $3.1 million for the third quarter of 2008. The net loss for the three months ended September 30, 2008, which included $2.5 million in restructuring charges, was $16.3 million, or $0.33 per share compared to a net loss of $11.3 million, or $0.24 per share for the same period in 2007. As of September 30, 2008, cash, cash equivalents, restricted cash and long-term investments totaled...

2008-10-30 12:01:04

Infinity Pharmaceuticals, a cancer drug discovery and development company, has announced that it has met pre-specified criteria to expand both arms of its ongoing Phase II clinical trial evaluating IPI-504, its lead heat shock protein 90 inhibitor, in patients with advanced non-small cell lung cancer. The study is designed to evaluate IPI-504 as a monotherapy in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) whose tumors have relapsed or become refractory to prior treatment...

2008-10-30 03:00:13

OXiGENE, a biopharmaceutical company, has reported positive interim results from an ongoing Phase II study of Zybrestat in patients with platinum-resistant ovarian cancer. The company said that 10 of 34 evaluable patients (29%) enrolled to date in the ongoing, single-arm, Simon two-stage design study evaluating the combination of Zybrestat and chemotherapy (carboplatin and paclitaxel) had partial responses as measured by tumor imaging and/or ovarian cancer biomarker (CA-125) criteria. An...

2008-10-28 09:00:39

Onconova Therapeutics, Inc. announced today the publication of positive results from a first-in-human Phase I clinical trial of its lead anticancer drug, ON 01910.Na, in advanced refractory solid tumors. The publication will be online today in the Journal of Clinical Oncology and will appear in a future print edition of the journal. A first-in-class targeted therapy, ON 01910.Na is a potent and selective mitotic pathway modulator that selectively disrupts the cell cycle transition in cancer...

2008-10-26 09:00:07

Proteolix has reported positive data from a Phase I clinical trial of carfilzomib in patients with advanced solid tumors. The Phase I clinical trial was designed to assess the safety, pharmacokinetics and pharmacodynamics of carfilzomib among patients with advanced solid tumors who had previously failed at least two rounds of prior treatment with approved chemotherapies. Patients received carfilzomib administered for two consecutive days for each of the first three weeks on a four-week...

2008-10-24 09:00:07

Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research, has completed the IT-101 Phase I clinical study conducted at City of Hope in Duarte, California. The company expects the entire study data to be published in early 2009. IT-101 is an experimental, nanoparticle therapeutic that consists of the drug camptothecin conjugated to a cyclodextrin polymer. IT-101, the first drug candidate in Calando's proprietary Cyclosert pipeline, has now successfully completed a Phase I...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'